ATPWhat was measured
Measured, with no finding
125 endpoints
Show what was measuredHide what was measured
muscular strength (1RM and repetitions to fatigue at 70% of 1RM) and Wingate 30 s anaerobic power (peak PO, total work, average PO), after 14 days of enteric-coated oral ATP at 150 mg or 225 mg daily against placebo
no effect, no significant between group treatment effects for any muscular strength parameter
Not recorded as a finding: the supporting sentence never names the compound
Overall, we observed no significant between group treatment effects for any muscular strength parameter.
PMID 15179168 · one of two readings recorded this
muscular strength parameters (between groups)
no effect
Overall, we observed no significant between group treatment effects for any muscular strength parameter
PMID 15179168 · one of two readings recorded this
one-repetition maximum (1RM), within group change
increases, p = 0.04
1RM (6.6%; P < 0.04)
PMID 15179168 · one of two readings recorded this
plasma ATP concentration
no effect
Statistical analyses showed no significant between or within group treatment effects for whole blood ATP or plasma ATP concentrations for any treatment condition
PMID 15179168 · one of two readings recorded this
post-Wingate lactate accumulation
no effect
We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation
PMID 15179168 · one of two readings recorded this
repetitions to fatigue, set 1 of posttesting, within group change
increases, p = 0.007
repetitions to fatigue during set 1 of posttesting (18.5%; P < 0.007)
PMID 15179168 · one of two readings recorded this
total lifting volume at post, within group change
increases, p = 0.003
total lifting volume at post (22%; P < 0.003)
PMID 15179168 · one of two readings recorded this
whole blood ATP concentration
no effect
Statistical analyses showed no significant between or within group treatment effects for whole blood ATP or plasma ATP concentrations for any treatment condition
PMID 15179168 · one of two readings recorded this
Wingate 30 s anaerobic test parameters (peak power output, total work, average power, post-Wingate lactate) after 14 d of enteric-coated oral ATP 150 mg or 225 mg vs placebo
no effect, no treatment effects for any Wingate testing parameter
Not recorded as a finding: the supporting sentence never names the compound
We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation.
PMID 15179168 · one of two readings recorded this
Wingate average power output (average PO) for 30 s
no effect
We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation
PMID 15179168 · one of two readings recorded this
Wingate peak power output (peak PO)
no effect
We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation
PMID 15179168 · one of two readings recorded this
Wingate total work
no effect
We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation
PMID 15179168 · one of two readings recorded this
overall assessments of efficacy by patient and investigator
no effect
There were no statistically significant differences in the VAS pain and overall assessments of efficacy between groups at any time point during the study
PMID 15940776 · one of two readings recorded this
Roland-Morris Disability Questionnaire (RDQ), between-group difference
no effect, p = 0.2
The difference between the 2 groups was statistically significant at day 7 (p= 0.02) but not at day 30 (p=0.2)
PMID 15940776 · one of two readings recorded this
Roland-Morris Disability Questionnaire (RDQ), between-group difference
decreases, p = 0.02
The difference between the 2 groups was statistically significant at day 7 (p= 0.02) but not at day 30 (p=0.2)
PMID 15940776 · one of two readings recorded this
Roland-Morris Disability Questionnaire (RDQ), mean change from baseline
no effect, p = 0.78
5.1 +/- 3.9 and 5.0 +/- 4.2 at day 30 (p=0.78)
PMID 15940776 · one of two readings recorded this
Roland-Morris Disability Questionnaire (RDQ), mean change from baseline
no effect, p = 0.06
the mean changes from baseline were 2.8 +/- 3.1 and 2.0 +/- 2.6 at day 7 (p=0.06)
PMID 15940776 · one of two readings recorded this
Roland-Morris Disability Questionnaire (RDQ)
decreases
the mean values dropped from 10.3 +/-2.8 at baseline to 7.5 +/-3.8 (day 7) and 5.2 +/-5.2 (day 30) in the ATP group
PMID 15940776 · one of two readings recorded this
Roland-Morris Disability Questionnaire (RDQ)
decreases
the mean values dropped from 10.3 +/-2.8 at baseline to 7.5 +/-3.8 (day 7) and 5.2 +/-5.2 (day 30) in the ATP group
PMID 15940776 · one of two readings recorded this
Roland-Morris Disability Questionnaire (RDQ)
decreases
from 11.0 +/- 3.5 to 9.1 +/- 4.2 (day 7) and 6.1 +/- 4.3 (day 30) in the placebo group
PMID 15940776 · one of two readings recorded this
Roland-Morris Disability Questionnaire (RDQ)
decreases
from 11.0 +/- 3.5 to 9.1 +/- 4.2 (day 7) and 6.1 +/- 4.3 (day 30) in the placebo group
PMID 15940776 · one of two readings recorded this
use of rescue analgesic (dextropropoxyphene and acetaminophen combination tablets)
decreases, p = 0.04
there was a significant difference in the use of the rescue analgesic between groups, in favor of ATP (p=0.04)
PMID 15940776 · one of two readings recorded this
visual analog scale pain in subacute low back pain, 90 mg oral ATP once daily against placebo for one month; the primary measure was the Roland-Morris Disability Questionnaire at day 30, and rescue analgesic tablet use was also counted
no effect, no statistically significant differences between groups at any time point
Not recorded as a finding: the supporting sentence never names the compound
There were no statistically significant differences in the VAS pain and overall assessments of efficacy between groups at any time point during the study.
PMID 15940776 · one of two readings recorded this
visual analog scale pain in subacute low back pain, ATP 90 mg once daily vs placebo for one month
no effect, no statistically significant differences between groups at any time point
Not recorded as a finding: the supporting sentence never names the compound
There were no statistically significant differences in the VAS pain and overall assessments of efficacy between groups at any time point during the study.
PMID 15940776 · one of two readings recorded this
visual analog scale (VAS) pain
no effect
There were no statistically significant differences in the VAS pain and overall assessments of efficacy between groups at any time point during the study
PMID 15940776 · one of two readings recorded this
five-hour total urine volume
n = 33
Control1 | 0.14 (0.08–0.22) | 4.41 (3.31–5.88) | 298 (182–613)
PMID 17578566 · one of two readings recorded this
five-hour total urine volume
n = 33
Indomethacin + adenosine | 0.23 (0.11–0.28)* | 4.52 (3.90–5.26) | 307 (213–563)
PMID 17578566 · one of two readings recorded this
five-hour total urine volume
n = 33
Indomethacin + ATP | 0.18 (0.12–0.32)* | 4.12 (3.23–4.89) | 371 (165–518)
PMID 17578566 · one of two readings recorded this
five-hour total urine volume
n = 33
Indomethacin + placebo | 0.20 (0.11–0.31)* | 4.60 (3.15–5.91) | 324 (193–493)
PMID 17578566 · one of two readings recorded this
urinary L/R excretion ratio versus control
increases, p = 0.01, n = 33
Median L/R ratios after indomethacin ingestion with administration of ATP or adenosine remained significantly increased compared to the L/R ratio in the control condition (P < 0.01, Fig. 1)
PMID 17578566 · one of two readings recorded this
urinary L/R excretion ratio versus control
increases, p = 0.01, n = 33
Median L/R ratios after indomethacin ingestion with administration of ATP or adenosine remained significantly increased compared to the L/R ratio in the control condition (P < 0.01, Fig. 1)
PMID 17578566 · one of two readings recorded this
urinary L/R excretion ratio
increases, p = 0.01, n = 33
After ingestion of indomethacin plus placebo, the median L/R ratio was significantly increased to 0.039 (0.035–0.068; P < 0.01 vs. control)
PMID 17578566 · one of two readings recorded this
urinary L/R excretion ratio
no effect, p = 0.49, n = 33
median L/R ratio after ingestion of indomethacin plus adenosine was 0.050 (0.030–0.067; P = 0.49 vs. placebo)
PMID 17578566 · one of two readings recorded this
urinary L/R excretion ratio
no effect, p = 0.22, n = 33
Median L/R ratio after ingestion of indomethacin plus ATP was 0.047 (0.033–0.065; P = 0.22 vs. placebo)
PMID 17578566 · one of two readings recorded this
urinary L-rhamnose recovery
n = 33
Control1 | 0.14 (0.08–0.22) | 4.41 (3.31–5.88) | 298 (182–613)
PMID 17578566 · one of two readings recorded this
urinary L-rhamnose recovery
n = 33
Indomethacin + adenosine | 0.23 (0.11–0.28)* | 4.52 (3.90–5.26) | 307 (213–563)
PMID 17578566 · one of two readings recorded this
urinary L-rhamnose recovery
n = 33
Indomethacin + ATP | 0.18 (0.12–0.32)* | 4.12 (3.23–4.89) | 371 (165–518)
PMID 17578566 · one of two readings recorded this
urinary L-rhamnose recovery
n = 33
Indomethacin + placebo | 0.20 (0.11–0.31)* | 4.60 (3.15–5.91) | 324 (193–493)
PMID 17578566 · one of two readings recorded this
urinary lactulose recovery, ATP versus placebo
no effect, n = 33
Neither administration of ATP nor of adenosine affected the indomethacin-induced increase in lactulose permeation
PMID 17578566 · one of two readings recorded this
urinary lactulose recovery over 5 h, percent of ingested dose, HPLC with pulsed amperometric detection
no effect
Not recorded as a finding: No outcome node for urinary lactulose recovery alone; the node covers only the lactulose/rhamnose ratio. The sentence also pools ATP with adenosine.
Neither administration of ATP nor of adenosine affected the indomethacin-induced increase in lactulose permeation.
PMID 17578566 · one of two readings recorded this
urinary lactulose recovery versus control
increases, p = 0.01, n = 33
Compared to lactulose recovery in the control condition (0.14% (0.08–0.22%)), urinary lactulose recovery was significantly increased by ingestion of indomethacin plus placebo (0.20% (0.11–0.31%); P < 0.01)
PMID 17578566 · one of two readings recorded this
urinary lactulose recovery versus control
increases, p = 0.01, n = 33
Lactulose recovery after ingestion of capsules with ATP was 0.18% (0.12–0.32%) and was 0.23% (0.11–0.28%) after ingestion of capsules with adenosine; both these values remained significantly increased compared to the control condition (P < 0.01)
PMID 17578566 · one of two readings recorded this
urinary lactulose recovery versus control
increases, p = 0.01, n = 33
Lactulose recovery after ingestion of capsules with ATP was 0.18% (0.12–0.32%) and was 0.23% (0.11–0.28%) after ingestion of capsules with adenosine; both these values remained significantly increased compared to the control condition (P < 0.01)
PMID 17578566 · one of two readings recorded this
urinary lactulose recovery
n = 33
Control1 | 0.14 (0.08–0.22) | 4.41 (3.31–5.88) | 298 (182–613)
PMID 17578566 · one of two readings recorded this
urinary lactulose recovery
n = 33
Indomethacin + adenosine | 0.23 (0.11–0.28)* | 4.52 (3.90–5.26) | 307 (213–563)
PMID 17578566 · one of two readings recorded this
urinary lactulose recovery
n = 33
Indomethacin + ATP | 0.18 (0.12–0.32)* | 4.12 (3.23–4.89) | 371 (165–518)
PMID 17578566 · one of two readings recorded this
urinary lactulose recovery
n = 33
Indomethacin + placebo | 0.20 (0.11–0.31)* | 4.60 (3.15–5.91) | 324 (193–493)
PMID 17578566 · one of two readings recorded this
urinary lactulose/rhamnose (L/R) excretion ratio
n = 33
Median L/R ratio (g/g) in the control condition (no indomethacin, no ATP/adenosine) was 0.032 (interquartile range: 0.022–0.044)
PMID 17578566 · one of two readings recorded this
blood and plasma ATP concentration after 28 days of daily enteric-coated oral ATP (0, 250, 1250 or 5000 mg)
no effect, no change in blood or plasma ATP concentrations after 4 weeks
Not recorded as a finding: this platform holds no node for the endpoint
ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations.
PMID 21129239 · one of two readings recorded this
blood and plasma ATP concentrations after 28 days of daily oral enteric-coated ATP pellets at 0, 250, 1250 or 5000 mg per day; plasma uric acid after a 5000 mg ATP dose was also measured
no effect, no change in blood or plasma ATP concentrations after 4 weeks of supplementation
Not recorded as a finding: this platform holds no node for the endpoint
ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations.
PMID 21129239 · one of two readings recorded this
blood ATP concentration
no effect
ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations
PMID 21129239 · one of two readings recorded this
liver and kidney parameters (safety)
no effect
Prolonged administration of ATP was safe as evidenced from liver and kidney parameters
PMID 21129239 · one of two readings recorded this
plasma ATP concentration
no effect
ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations
PMID 21129239 · one of two readings recorded this
plasma uric acid
increases
Of all ATP metabolites, only plasma uric acid levels increased significantly after the administration of 5000 mg of ATP
PMID 21129239 · one of two readings recorded this
ADP formed from ATP during dissolution
ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)
PMID 22510240 · one of two readings recorded this
ADP formed from ATP during dissolution
ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)
PMID 22510240 · one of two readings recorded this
AMP formed from ATP during dissolution
ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)
PMID 22510240 · one of two readings recorded this
AMP formed from ATP during dissolution
ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)
PMID 22510240 · one of two readings recorded this
ATP released from pellets after 120 min in 0.1 N HCl (dissolution test)
After staying for 120 min in 0.1 N HCl, less than 5% ATP (5.0 ± 0.6% for the proximal-release pellets and 3.4 ± 0.4% for the distal-release pellets) was released from the pellets
PMID 22510240 · one of two readings recorded this
ATP released from pellets after 120 min in 0.1 N HCl (dissolution test)
After staying for 120 min in 0.1 N HCl, less than 5% ATP (5.0 ± 0.6% for the proximal-release pellets and 3.4 ± 0.4% for the distal-release pellets) was released from the pellets
PMID 22510240 · one of two readings recorded this
plasma lithium AUC, ATP-containing versus placebo proximal-release pellets
decreases, p = 0.001
the lithium AUC was significantly lower in the ATP-containing pellets than in the placebo-containing ones (P = 0.001)
PMID 22510240 · one of two readings recorded this
plasma lithium AUC, proximal-release versus distal-release ATP pellets
increases, p = 0.001
the proximal-release pellets caused a significantly higher increase in plasma lithium than the distal-release pellets (P = 0.001)
PMID 22510240 · one of two readings recorded this
plasma lithium AUC (release marker)
ATP (420 min) | 25.4 ± 5.7 d,e | 0.30 ± 0.03 | 240 | 65174 ± 7985 f
PMID 22510240 · one of two readings recorded this
plasma lithium AUC (release marker)
Placebo (420 min) | 0.9 ± 1.1 | 0.20 ± 0.02 | n.a. | 117914 ± 15021 f
PMID 22510240 · one of two readings recorded this
plasma lithium AUC (release marker)
ATP (420 min) | 3.2 ± 1.4 | 0.22 ± 0.02 | 390 | 12575 ± 2832 f
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
no effect
Administration of ATP by distal-release pellets did not lead to a significantly increased uric acid AUC, compared to placebo
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
increases, p = 0.003
Compared to placebo, the uric acid AUC increased significantly when ATP was administered by proximal-release pellets (P = 0.003) or by naso-duodenal tube (P = 0.001)
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
increases, p = 0.001
Compared to placebo, the uric acid AUC increased significantly when ATP was administered by proximal-release pellets (P = 0.003) or by naso-duodenal tube (P = 0.001)
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
no effect
ATP (270 min) | 1.7 ± 1.1 | n.a. | n.a. | n.a.
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
no effect
ATP (420 min) | 3.2 ± 1.4 | 0.22 ± 0.02 | 390 | 12575 ± 2832 f
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
increases
ATP (270 min) | 16.1 ± 3.0 | n.a. | n.a. | n.a.
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
increases
ATP (420 min) | 25.4 ± 5.7 d,e | 0.30 ± 0.03 | 240 | 65174 ± 7985 f
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
increases
ATP (270 min) | 19.6 ± 4.4 a,b,c | 0.31 ± 0.03 | 135 | n.a.
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
Placebo (270 min) | 0.8 ± 0.9 | n.a. | n.a. | n.a.
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
Placebo (420 min) | 0.9 ± 1.1 | 0.20 ± 0.02 | n.a. | 117914 ± 15021 f
PMID 22510240 · one of two readings recorded this
uric acid AUC (blood)
Placebo (270 min) | −0.4 ± 0.4 | 0.21 ± 0.03 | n.a. | n.a.
PMID 22510240 · one of two readings recorded this
uric acid formed from ATP during dissolution
ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)
PMID 22510240 · one of two readings recorded this
uric acid formed from ATP during dissolution
ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)
PMID 22510240 · one of two readings recorded this
whole-blood ATP concentration after a single 5000 mg oral ATP dose, HPLC, AUC over 4.5-7 h
no effect, no statistically significant differences between placebo and ATP for any type of administration (data not shown)
Not recorded as a finding: this platform holds no node for the endpoint
HPLC analysis of the whole blood showed that ATP concentrations were stable over time, and that there were no statistically significant differences between placebo and ATP supplements for any type of administration (data not shown).
PMID 22510240 · one of two readings recorded this
whole-blood ATP concentration over time, HPLC with UV detection, after a single 5000 mg dose of enteric-coated ATP pellets or ATP via naso-duodenal tube against placebo; whole-blood uric acid AUC by the same HPLC method was also measured
no effect, no statistically significant differences between placebo and ATP for any administration type (data not shown)
Not recorded as a finding: this platform holds no node for the endpoint
HPLC analysis of the whole blood showed that ATP concentrations were stable over time, and that there were no statistically significant differences between placebo and ATP supplements for any type of administration (data not shown).
PMID 22510240 · one of two readings recorded this
whole-blood ATP concentration
no effect
ATP concentrations were stable over time, and that there were no statistically significant differences between placebo and ATP supplements for any type of administration
PMID 22510240 · one of two readings recorded this
pain scores at postoperative days 7, 14, 21 and 28, quadriceps strength and total opioid consumption after total knee arthroplasty, 120 mg oral ATP daily against placebo for 4 weeks
Not recorded as a finding: the paper never states the instrument the node requires
Significant differences in quadriceps strength, pain scores at postoperative days 7, 14, 21, and 28 and total opioid consumption were detected.
PMID 24813646 · one of two readings recorded this
pain scores
unclear
Significant differences in quadriceps strength, pain scores at postoperative days 7, 14, 21, and 28 and total opioid consumption were detected
PMID 24813646 · one of two readings recorded this
quadriceps strength
unclear
Significant differences in quadriceps strength, pain scores at postoperative days 7, 14, 21, and 28 and total opioid consumption were detected
PMID 24813646 · one of two readings recorded this
total opioid consumption
unclear
Significant differences in quadriceps strength, pain scores at postoperative days 7, 14, 21, and 28 and total opioid consumption were detected
PMID 24813646 · one of two readings recorded this
muscle activation
no effect
No group by time interaction was observed for muscle activation
PMID 28080323 · one of two readings recorded this
muscle excitability in later bouts
no effect
ATP supplementation prevented the decline in later bouts
PMID 28080323 · one of two readings recorded this
muscle excitability
decreases, p = 0.02
muscle excitability significantly decreased in later bouts 8, 9, and 10 in the placebo group (-30.5, -28.3, and -27.9%, respectively; p < 0.02)
PMID 28080323 · one of two readings recorded this
muscle excitability
decreases, p = 0.02
muscle excitability significantly decreased in later bouts 8, 9, and 10 in the placebo group (-30.5, -28.3, and -27.9%, respectively; p < 0.02)
PMID 28080323 · one of two readings recorded this
muscle excitability
decreases, p = 0.02
muscle excitability significantly decreased in later bouts 8, 9, and 10 in the placebo group (-30.5, -28.3, and -27.9%, respectively; p < 0.02)
PMID 28080323 · one of two readings recorded this
postexercise ADP level
no effect, p = 0.05
Oral ATP supplementation prevented a drop in ATP, adenosine-5'-diphosphate (ADP), and adenosine-5'-monophosphate (AMP) levels postexercise (p < 0.05)
PMID 28080323 · one of two readings recorded this
postexercise AMP level
no effect, p = 0.05
Oral ATP supplementation prevented a drop in ATP, adenosine-5'-diphosphate (ADP), and adenosine-5'-monophosphate (AMP) levels postexercise (p < 0.05)
PMID 28080323 · one of two readings recorded this
postexercise ATP level
no effect, p = 0.05
Oral ATP supplementation prevented a drop in ATP, adenosine-5'-diphosphate (ADP), and adenosine-5'-monophosphate (AMP) levels postexercise (p < 0.05)
PMID 28080323 · one of two readings recorded this
Wingate peak power
increases
ATP significantly increased Wingate peak power in later bouts compared to baseline (bout 8: +18.3%, bout 10: +16.3%)
PMID 28080323 · one of two readings recorded this
Wingate peak power
increases
ATP significantly increased Wingate peak power in later bouts compared to baseline (bout 8: +18.3%, bout 10: +16.3%)
PMID 28080323 · one of two readings recorded this
Wingate test peak power across repeated sprint bouts, 400 mg oral ATP disodium salt against placebo for 2 weeks; also muscle excitability (ratio of power output to muscle activation) and blood ATP, ADP and AMP after exercise
increases, within-arm change from baseline: bout 8 +18.3%, bout 10 +16.3%
Not recorded as a finding: the result compares a group with itself, not with a control
ATP significantly increased Wingate peak power in later bouts compared to baseline (bout 8: +18.3%, bout 10: +16.3%).
PMID 28080323 · one of two readings recorded this
Wingate test peak power across ten repeated sprint bouts after 2 weeks of 400 mg oral ATP or placebo
increases, bout 8: +18.3%, bout 10: +16.3% versus baseline in the ATP group
Not recorded as a finding: the result compares a group with itself, not with a control
ATP significantly increased Wingate peak power in later bouts compared to baseline (bout 8: +18.3%, bout 10: +16.3%).
PMID 28080323 · one of two readings recorded this
blood lactate
no effect
There were no differences between conditions for lactate and blood pressure
PMID 29045315 · one of two readings recorded this
blood pressure
no effect
There were no differences between conditions for lactate and blood pressure
PMID 29045315 · one of two readings recorded this
heart rate
increases, p = 0.001
Heart rate was higher at set-4 for ATP compared with placebo (p < 0.001)
PMID 29045315 · one of two readings recorded this
oxygen consumption during exercise
increases, p = 0.021
oxygen consumption during exercise was greater for ATP (p = 0.021)
PMID 29045315 · one of two readings recorded this
total weight lifted in 4 sets of half-squats to momentary muscular failure at 80% of 1RM, 400 mg oral ATP against placebo
increases, p = 0.005
Not recorded as a finding: a node exists but the paper states a different instrument or population
The total weight lifted were higher for the ATP condition compared with placebo (Placebo = 3,995.7 ± 1,137.8, ATP = 4,967.4 ± 1,497.9 kg; p = 0.005).
PMID 29045315 · one of two readings recorded this
total weight lifted (kg) over 4 sets of half-squats to momentary muscular failure at 80% of 1RM
increases, p = 0.005
Not recorded as a finding: a node exists but the paper states a different instrument or population
The total weight lifted were higher for the ATP condition compared with placebo (Placebo = 3,995.7 ± 1,137.8, ATP = 4,967.4 ± 1,497.9 kg; p = 0.005).
PMID 29045315 · one of two readings recorded this
total weight lifted
increases, p = 0.005
(Placebo = 3,995.7 ± 1,137.8, ATP = 4,967.4 ± 1,497.9 kg; p = 0.005)
PMID 29045315 · one of two readings recorded this
diastolic blood pressure across recovery
no effect, p = 0.05
For DBP (mmHg), there was no main effect of time, interaction and conditions (P>0.05)
PMID 30276192 · one of two readings recorded this
diastolic blood pressure after exercise, automatic Omron cuff monitor
no effect, no main effect of time, interaction or conditions
Not recorded as a finding: The only sentence is agentless and never names ATP; the subject lives in the previous sentence.
For DBP (mmHg), there was no main effect of time, interaction and conditions (P>0.05).
PMID 30276192 · one of two readings recorded this
exercise intensity
no effect
For exercise intensity, no significant difference was observed between trials
PMID 30276192 · one of two readings recorded this
heart rate during recovery
no effect
For HR (bpm) there was a main effect of time (F=19.249, P<0.001, η2=0.68) with higher HR for placebo and ATP in relation to rest, however, no significant difference were observed between trials
PMID 30276192 · one of two readings recorded this
HF power delta (recovery minus rest)
unclear, p = 0.05
there was a trend to a significant difference in the HFmsec2 (ATP=5.1±77.6 msec2 vs. Placebo= −55.3±80.5 msec2, P=0.05)
PMID 30276192 · one of two readings recorded this
HF power (msec2) during recovery
no effect, p = 0.05
Regarding frequency domain (LFmsec2 and HFmsec2), there were no significant difference during recovery (P>0.05)
PMID 30276192 · one of two readings recorded this
HFnu during recovery
no effect, p = 0.05
For LFnu, HFnu, and LF/HF ratio, there were no statistically significant difference during recovery between conditions (P>0.05)
PMID 30276192 · one of two readings recorded this
LF/HF ratio during recovery
no effect, p = 0.05
For LFnu, HFnu, and LF/HF ratio, there were no statistically significant difference during recovery between conditions (P>0.05)
PMID 30276192 · one of two readings recorded this
LF power delta (recovery minus rest)
increases, p = 0.028
LFmsec2 was statistically lower for placebo in relation to ATP (ATP=−19.9±122.7 msec2 vs. placebo=−94.2± 200.3 msec2, P=0.028)
PMID 30276192 · one of two readings recorded this
LF power (msec2) during recovery
no effect, p = 0.05
Regarding frequency domain (LFmsec2 and HFmsec2), there were no significant difference during recovery (P>0.05)
PMID 30276192 · one of two readings recorded this
LFnu during recovery
no effect, p = 0.05
For LFnu, HFnu, and LF/HF ratio, there were no statistically significant difference during recovery between conditions (P>0.05)
PMID 30276192 · one of two readings recorded this
RMSSD delta (recovery minus rest)
increases, p = 0.009
For RMSSD, there was a significant greater values for ATP compared to placebo (ATP=2.2±7.2 msec vs. placebo=−4.7±7.6 msec; P=0.009)
PMID 30276192 · one of two readings recorded this
RMSSD during recovery
increases, p = 0.027
For RMSSD, there was statistically significant difference during recovery (F=4.917, P=0.020, η2=0.35), with significant higher RMSSD for ATP compared to placebo (P=0.027)
PMID 30276192 · one of two readings recorded this
SDNN delta (recovery minus rest)
increases, p = 0.014
delta analysis showed significant higher SDNN for ATP (ATP=3.1±10.8 msec vs. placebo=−2.9±8.5 msec, P=0.014)
PMID 30276192 · one of two readings recorded this
SDNN during recovery
increases, p = 0.041
When analyzed SDNN, there was no statistically significant difference (F=2.414, P=0.118, η2=0.21), however, Bonferroni post hoc demonstrated significant greater SNDD in the ATP conditions compared to placebo (P=0.041)
PMID 30276192 · one of two readings recorded this
systolic blood pressure across recovery, condition effect
no effect, p = 0.05
Regarding SBP (mmHg), there was a main effect of time (F=12.649, P<0.001, η2=0.55), but no difference between conditions and interaction were verified (P>0.05)
PMID 30276192 · one of two readings recorded this
systolic blood pressure change 20 min after exercise (post-20 minus rest), automatic Omron monitor, supine after exercise
decreases, delta SBP ATP -13.18 +/- 8.3 vs placebo -6.1 +/- 9.9 mmHg, p = 0.006
Not recorded as a finding: Node systolic-blood-pressure-unspecified-setting is for sources that do not record acquisition conditions; here the post-exercise supine protocol is recorded, and the office node requires a seated clinic reading. Near miss on setting.
However, when analyzed the delta (Δ=post-20 min minus rest), there was a significant lower SBP for ATP compared to placebo (ATP= −13.18±8.3 mm/Hg vs. placebo=−6.1±9.9 mm/Hg, P=0.006).
PMID 30276192 · one of two readings recorded this
systolic blood pressure delta (post-20 min minus rest)
decreases, p = 0.006
there was a significant lower SBP for ATP compared to placebo (ATP= −13.18±8.3 mm/Hg vs. placebo=−6.1±9.9 mm/Hg, P=0.006)
PMID 30276192 · one of two readings recorded this
fatigue level as exercise progressed
decreases
it was able to reduce fatigue levels as the exercise progressed
PMID 38193939 · one of two readings recorded this
knee extension and flexion muscle strength indicators and resistance to fatigue over five isokinetic sets at 60 degrees per second, Biodex 4.0 isokinetic dynamometer, 400 mg Peak ATP against placebo
Not recorded as a finding: this platform holds no node for the endpoint
An acute dose of 400 mg of ATP did not improve the volunteers' muscle strength indicators, but it was able to reduce fatigue levels as the exercise progressed, enabling greater performance for longer.
PMID 38193939 · one of two readings recorded this
muscle strength indicators
no effect
Acute supplementation was unable to achieve significant improvements in muscle strength indicators
PMID 38193939 · one of two readings recorded this